2025 Q4 -tulosraportti
61 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenHow does it look in 6 months? What do you think?
·29 min sittenEverything depends on earnings and growth. No one knows that. A little more openness and optimism signaled from NN will help in the short term. Furthermore, Lars Rebien must be replaced and then the large investors will return. That will have a big effect. Next quarter's report will make us wiser.
·1 t sitten · MuokattuAfter Nordisk Fjer has left the establishment, karbonhappy, OldBB, Halvhjerne and a couple more continue to uphold their negative mud-slinging. This segment must soon find another object of hatred for obvious reasons. Good evening to all of you who do not let yourselves be cowed by these pathetic village idiots.
·2 t sittenNovo's pill is both better and cheaper. Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA at the beginning of 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication containing orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients who took weight loss medication with orforglipron. The Danish pharmaceutical company writes this in a press release. The American drug agency, FDA, approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron, on Wednesday. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA at the beginning of 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. hus NEWS Read also: Apartments evacuated after partial collapse of gable The obesity conference will be held from April 10 to April 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substances semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. en kæberest NEWS Read also: Archaeologists vacuumed Danish ship and found human jaw Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. The pill will, according to the media MarketWire, be launched at a price of 149 dollar per month for the lowest dose for self-paying individuals. Americans covered by the public health insurance Medicare can get the pill for 50 dollar per month. Novo Nordisk's pill also costs 149 dollar per month for self-paying users. From August 31, the price will increase to 199 dollar per month. For people covered by health insurance, the price starts at 25 dollar per month, according to MarketWire. /ritzau
·3 t sittenLLY's pills are cheaper, better, and can be taken anytime during the day. Tomorrow the Danish clowns will slash NN's price. Glad I have gotten out, for 180kr is the next stop. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
61 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenHow does it look in 6 months? What do you think?·29 min sittenEverything depends on earnings and growth. No one knows that. A little more openness and optimism signaled from NN will help in the short term. Furthermore, Lars Rebien must be replaced and then the large investors will return. That will have a big effect. Next quarter's report will make us wiser.
- ·1 t sitten · MuokattuAfter Nordisk Fjer has left the establishment, karbonhappy, OldBB, Halvhjerne and a couple more continue to uphold their negative mud-slinging. This segment must soon find another object of hatred for obvious reasons. Good evening to all of you who do not let yourselves be cowed by these pathetic village idiots.
- ·2 t sittenNovo's pill is both better and cheaper. Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA at the beginning of 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication containing orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients who took weight loss medication with orforglipron. The Danish pharmaceutical company writes this in a press release. The American drug agency, FDA, approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron, on Wednesday. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA at the beginning of 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. hus NEWS Read also: Apartments evacuated after partial collapse of gable The obesity conference will be held from April 10 to April 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substances semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. en kæberest NEWS Read also: Archaeologists vacuumed Danish ship and found human jaw Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. The pill will, according to the media MarketWire, be launched at a price of 149 dollar per month for the lowest dose for self-paying individuals. Americans covered by the public health insurance Medicare can get the pill for 50 dollar per month. Novo Nordisk's pill also costs 149 dollar per month for self-paying users. From August 31, the price will increase to 199 dollar per month. For people covered by health insurance, the price starts at 25 dollar per month, according to MarketWire. /ritzau
- ·3 t sittenLLY's pills are cheaper, better, and can be taken anytime during the day. Tomorrow the Danish clowns will slash NN's price. Glad I have gotten out, for 180kr is the next stop. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
61 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenHow does it look in 6 months? What do you think?·29 min sittenEverything depends on earnings and growth. No one knows that. A little more openness and optimism signaled from NN will help in the short term. Furthermore, Lars Rebien must be replaced and then the large investors will return. That will have a big effect. Next quarter's report will make us wiser.
- ·1 t sitten · MuokattuAfter Nordisk Fjer has left the establishment, karbonhappy, OldBB, Halvhjerne and a couple more continue to uphold their negative mud-slinging. This segment must soon find another object of hatred for obvious reasons. Good evening to all of you who do not let yourselves be cowed by these pathetic village idiots.
- ·2 t sittenNovo's pill is both better and cheaper. Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA at the beginning of 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication containing orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients who took weight loss medication with orforglipron. The Danish pharmaceutical company writes this in a press release. The American drug agency, FDA, approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron, on Wednesday. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA at the beginning of 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. hus NEWS Read also: Apartments evacuated after partial collapse of gable The obesity conference will be held from April 10 to April 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substances semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. en kæberest NEWS Read also: Archaeologists vacuumed Danish ship and found human jaw Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. The pill will, according to the media MarketWire, be launched at a price of 149 dollar per month for the lowest dose for self-paying individuals. Americans covered by the public health insurance Medicare can get the pill for 50 dollar per month. Novo Nordisk's pill also costs 149 dollar per month for self-paying users. From August 31, the price will increase to 199 dollar per month. For people covered by health insurance, the price starts at 25 dollar per month, according to MarketWire. /ritzau
- ·3 t sittenLLY's pills are cheaper, better, and can be taken anytime during the day. Tomorrow the Danish clowns will slash NN's price. Glad I have gotten out, for 180kr is the next stop. Good luck!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt